Celyad Oncology SA: Celyad Oncology Announces First Quarter 2021 Financial Results and Recent Business Highlights
Enrollment continues in second dose cohort of Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for relapsed/refractory multiple myeloma (r/r MM); additional proof-of-concept data anticipated in second quarter 2021.
Expansion segment of Phase 1 alloSHRINK trial evaluating allogeneic CYAD-101 administered concurrently with preconditioning chemotherapy for the treatment of advanced metastatic colorectal cancer (mCRC) ongoing; preliminary data expected in mid-2021.
Phase 1b KEYNOTE-B79 trial evaluating CYAD-101 with KEYTRUDA in patients with microsatellite stable mCRC expected to be initiated in first half of 2021.
Regulatory News:
Share:
MONT-SAINT-GUIBERT, Belgium, May 05, 2021 (GLOBE NEWSWIRE) Celyad Oncology SA ((Euronext &, NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that it has received a transparency notification from Tolefi SA, dated 3 May 2021.
Tolefi SA has notified that its 2.295.701 shares benefit from a double voting right as of May 3, 2021 and that its shareholding has crossed above the threshold of 25%. The full transparency notice is available on the Celyad website under the heading Regulated Information .
A
bout Celyad Oncology SA
Celyad Oncology SA is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hemato
(0)
Regulatory News:
Celyad Oncology SA (Euronext Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that it has received a transparency notification from Tolefi SA, dated 3 May 2021.
Tolefi SA has notified that its 2.295.701 shares benefit from a double voting right as of May 3, 2021 and that its shareholding has crossed above the threshold of 25%. The full transparency notice is available on the Celyad website under the heading Regulated Information .
About Celyad Oncology SA
Celyad Oncology SA is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological ma
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
22nd Century Group Installs State-of-the-Art Nicotine Testing Equipment to Enhance VLN® Production
22nd Century Group, IncMay 5, 2021 GMT
BUFFALO, N.Y., May 05, 2021 (GLOBE NEWSWIRE) 22nd Century Group, Inc. (NYSE American: XXII ), a leading plant-based biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and hemp/cannabis research, announced today that it is advancing and expanding capabilities in its in-house laboratory, located in its cigarette manufacturing facility in Mocksville, North Carolina, for testing of its VLN® reduced nicotine content (RNC) tobacco and cigarettes. The Company estimates that its cost per VLN® sample will improve by more than 90% and the lead time for key data will take less than a day compared to using a third-party testing service that can take weeks.
Celyad Oncology SA: Celyad: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
1,802,756
created following the exercise of the attributed warrants
1,802,756
Warrants)
19.175.937
Contact person for regulated information (financial, transparency)
By law, any transparency declaration must be sent to our Company by email to the attention of Filippo Petti, Chief Executive Officer (CEO):
investors@celyad.com
investors@celyad.com
About Celyad Oncology
Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received